KAINOS Laboratories (TSE:4556) Piotroski F-Score: 5 (As of Jul. 11, 2026) — 17% Below Median


TSE:4556 KAINOS Laboratories Inc TSE:4556
39 GF Score
Price 円2,268.00
GF Value 円1,281.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is KAINOS Laboratories Piotroski F-Score?

KAINOS Laboratories TSE:4556 39 Piotroski F-Score is 5 as of Jul. 11, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,281.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, KAINOS Laboratories ranks better than 65.09% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

KAINOS Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for KAINOS Laboratories's Piotroski F-Score or its related term are showing as below:

TSE:4556' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of KAINOS Laboratories was 8. The lowest was 4. And the median was 6.

KAINOS Laboratories  (TSE:4556) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


KAINOS Laboratories Piotroski F-Score Related Terms


KAINOS Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for KAINOS Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KAINOS Laboratories Piotroski F-Score Chart

KAINOS Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 5.00 4.00 5.00

KAINOS Laboratories Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 0.00 4.00 0.00 5.00

TSE:4556 vs ISRG, BDX, MDLN: Piotroski F-Score Comparison

For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KAINOS Laboratories Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where KAINOS Laboratories's Piotroski F-Score falls into.


TSE:4556
39GF Score
KAINOS Laboratories Inc TSE:4556
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 円449 Mil.
Cash Flow from Operations was 円554 Mil.
Revenue was 円5,480 Mil.
Gross Profit was 円2,592 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (8785.144 + 9566.85) / 2 = 円9175.997 Mil.
Total Assets at the begining of this year (Mar25) was 円8,785 Mil.
Long-Term Debt & Capital Lease Obligation was 円329 Mil.
Total Current Assets was 円6,508 Mil.
Total Current Liabilities was 円1,963 Mil.
Net Income was 円641 Mil.

Revenue was 円5,306 Mil.
Gross Profit was 円2,674 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (8590.984 + 8785.144) / 2 = 円8688.064 Mil.
Total Assets at the begining of last year (Mar24) was 円8,591 Mil.
Long-Term Debt & Capital Lease Obligation was 円503 Mil.
Total Current Assets was 円5,821 Mil.
Total Current Liabilities was 円1,457 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

KAINOS Laboratories's current Net Income (TTM) was 449. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

KAINOS Laboratories's current Cash Flow from Operations (TTM) was 554. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=449.146/8785.144
=0.05112563

ROA (Last Year)=Net Income/Total Assets (Mar24)
=641.019/8590.984
=0.07461532

KAINOS Laboratories's return on assets of this year was 0.05112563. KAINOS Laboratories's return on assets of last year was 0.07461532. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

KAINOS Laboratories's current Net Income (TTM) was 449. KAINOS Laboratories's current Cash Flow from Operations (TTM) was 554. ==> 554 > 449 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=329.432/9175.997
=0.03590149

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=503.079/8688.064
=0.05790461

KAINOS Laboratories's gearing of this year was 0.03590149. KAINOS Laboratories's gearing of last year was 0.05790461. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=6507.93/1963.36
=3.31469012

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=5820.525/1456.639
=3.99585965

KAINOS Laboratories's current ratio of this year was 3.31469012. KAINOS Laboratories's current ratio of last year was 3.99585965. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

KAINOS Laboratories's number of shares in issue this year was 4.229. KAINOS Laboratories's number of shares in issue last year was 4.216. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2592.406/5479.789
=0.473085

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2674.365/5305.568
=0.50406761

KAINOS Laboratories's gross margin of this year was 0.473085. KAINOS Laboratories's gross margin of last year was 0.50406761. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5479.789/8785.144
=0.62375631

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=5305.568/8590.984
=0.61757396

KAINOS Laboratories's asset turnover of this year was 0.62375631. KAINOS Laboratories's asset turnover of last year was 0.61757396. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

KAINOS Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
KAINOS Laboratories (TSE:4556) has a Piotroski F-Score of 5 as of Jul. 11, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on KAINOS Laboratories and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, KAINOS Laboratories' Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, KAINOS Laboratories ranks #281 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 34.9%.
Is KAINOS Laboratories' Piotroski F-Score too high?
KAINOS Laboratories' current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. KAINOS Laboratories' value of 5 is 0% at this industry median. Based on the distribution chart, KAINOS Laboratories ranks #281 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' Piotroski F-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #281 out of 805 companies for Piotroski F-Score. This puts KAINOS Laboratories in the upper half of its industry. The industry median Piotroski F-Score is 5.00. KAINOS Laboratories' value of 5 is 0% at this benchmark. Historically, KAINOS Laboratories' own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, KAINOS Laboratories has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,281.99, compared to a current price of 円2,268.00 — trading 76.9% above its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Medical Devices & Instruments industry median of 5.00. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current Piotroski F-Score is 5 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?

Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued. The current stock price of 円2,268.00 is trading 76.9% above its estimated GF Value™ of 円1,281.99. GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.

Key valuation signals for TSE:4556:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: 円1,281.99 vs. price of 円2,268.00 (76.9% above fair value)
  • GF Score™: 39/100 with 6 warning signs
  • Industry Position: 0% at the Medical Devices & Instruments median (#281 of 805)

No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


KAINOS Laboratories Business Description

Address 38-18, Hongo 2-chome, Bunkyo-ku, Tokyo, JPN
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
39GF Score

Get the complete analysis for TSE:4556

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,268.00
Price
円1,281.99
GF Value